Poly(ethylene glycol) modification of β-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs

Cancer Immunology Immunotherapy

Volumn 44, Issue 6, 1997, Pages 305-315

  Cheng, Tian Lu ^a   Chen, Bing Mae ^a   Chan, Lai Yee ^a   Wu, Pin Yi ^a   Chern, Ji Wang ^b   Roffler, Steve R ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Glucuronidase; Cancer therapy; Monoclonal antibody; Poly(ethylene glycol); Prodrugs

Indexed keywords

4 AMINOPHENOL; ANTIBODY CONJUGATE; BETA GLUCURONIDASE; GLUCURONIDE; IMMUNOGLOBULIN G2A; MACROGOL; MONOCLONAL ANTIBODY RH1; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; ENZYME BLOOD LEVEL; ENZYME MODIFICATION; ESCHERICHIA COLI; GLUCURONIDATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR LOCALIZATION;

ANILINE MUSTARD; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ENZYME STABILITY; GLUCURONATES; GLUCURONIDASE; IMMUNOCONJUGATES; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; POLYETHYLENE GLYCOLS; PRODRUGS; RATS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030843862     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050387     Document Type: Article

References (44)

1. Haskell CM (1990) Principles and practice of cancer chemotherapy. In: Haskell CM (ed) Cancer treatment. Saunders, Philadelpia, p 21
2. Yeh MY, Roffler SR, Yu MH (1992) Doxorubicin-monoclonal antibody conjugate for therapy of human cervical carcinoma. Int J Cancer 51:274-282
3. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellström I, Hellström KE (1993) Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261:212-215
4. Schneider YJ, Abarca J, Aboud-Pirak E, Baurain R, Ceulemans F, Deprez-De Campeneere D, Lesur B, Masquelier M, Otte-Slachmuylder C, Rolin-van Swieten D, Trouet A (1984) Drug targeting in human cancer chemotherapy. In: Gregoriadis G, Poste G, Senior J, Trouet A (eds) Receptor-mediated targeting of drugs. Plenum, New York, p 1
5. Pirker R (1988) Immunotoxins against solid tumors. J Cancer Res Clin Oncol 114:385-393
6. Bagshawe KD (1987) Antibody directed enzymes revive anticancer prodrugs concept. Br J Cancer 56:531-532
7. Senter PD, Saulnier MG, Schreiber GJ, Hirschberg DL, Brown JP, Hellström I, Hellström KE (1988) Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 85:4842-4846
8. Blakey DC, Pinder PE, Wright AF (1994) Comparison of the cellular internalization of antibodies used either as immunotoxins or in ADEPT. Cell Biophys 24-25:175-183
9. Wallace PM, MacMaster JF, Smith VF, Kerr DE, Senter PD, Cosand WL (1994) Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res 54:2719-2723
10. Baxter LT, Jain RK (1996) Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data. Br J Cancer 73:447-456
11. Sherwood RF (1996) Advanced drug delivery reviews: enzyme prodrug therapy. Adv Drug Delivery Rev 22:269-288
12. Roffler SR, Wang SM, Chern JW, Yeh MY, Tung E (1991) Antineoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem Pharmacol 42:2062-2065
13. Wang SM, Chern JW, Yeh MY, Ng JC, Tung E, Roffler SR (1992) Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res 52:4484-4491
14. Stahl PD, Fishman WH (1984) β-D-glucuronidase. In: Bergmeyer J, Gral M (eds) Methods in enzymatic analysis, vol 5. Verlag Chemie, Weinheim, p 246
15. Dixon M, Webb EC (1979) Enzymes. Academic Press, New York, p 634
16. Hallinan T (1983) UDPglucuronosyltranferases. In: Bergmeyer J, Gral M (eds) Methods in enzymatic analysis, vol 3. Verlag Chemie, Weinheim, p 365
17. Weenen H, Van Maanen JMS, De Planque MM, MeVie JG, Pinedo HM (1984) Metabolism of 4′-modified analogs of doxorubicin. Unique glucuronidation pathway for 4′epidoxorubicin. Eur J Cancer Clin Oncol 20:419-926
18. Rivory LP, Robert J (1995) Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 36:176-179
19. Jefferson RA, Burgess SM, Hirsh D (1986) β-glucuronidase from Escherichia coli as a gene-fusion marker. Proc Natl Acad Sci USA 83:8447-8451
20. Haisma HJ, Boven E, Muijen M van, Jong J de, Vijgh WJ van der. Pinedo HM (1992) A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br J Cancer 66:474-478
21. Nolen H, Fedorak RN, Friend DR (1995) Budesonide-β-D-glucuronide: a potential prodrug for treatment of ulcerative colitis. J Pharm Sci 84:677-681
22. Houba PH, Leenders RG, Boven E, Seheeren JW, Pinedo HM, Haisma HJ (1996) Characterization of novel anthracycline prodrugs activated by human β-glucuronidase for use in antibody-directed enzyme prodrug therapy. Biochem Pharmacol 52:455-463
23. Roffler SR, Chan J, Yeh MY (1994) Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res 54:1276-1285
24. Nucci ML, Shorr R, Abuchowski A (1991) The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Delivery Rev 6:133-151
25. Delgado C, Francis GE, Fisher D (1992) The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 9:249-304
26. Smith DF, Walborg EF, Chang JP (1970) Establishment of a transplantable ascites variant of a rat hepatoma induced by 3′-methyl-4-dimethylaminoazobenzene. Cancer Res 30:2306-2309
27. Don RH, Cox PT, Wainwright BJ, Baker K, Mattick JS (1991) Touchdown PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res 19:4008
28. Yeh MY, Hellstrom I, Brown JP, Warner GA, Hansen JA, Hellstrom KE (1979) Cell surface antigens of human melanoma identified by monoclonal antibody. Proc Natl Acad Sci USA 76:2927-1931
29. Habeeb AFSA (1966) Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem 14:328-336
30. Wang SM (1992) Treatment of cancer with prodrugs activated by antibody targeted enzyme conjugates. PhD thesis, National Defence Medical School. Taipei
31. Koster JF, Slee RG (1977) Some properties of human liver acid α-glucosidase. Biochim Biophys Acta 482:89-97
32. Jain S, Drendel WB, Chen ZW, Mathews FS, Sly WS, Grubb JH (1996) Structure of human β-glucuronidase reveals candidate lysosomal targeting and active-site motifs. Nat Struct Biol 3:375-381
33. 2 derivative. J Inorg Biochem 39:149-159
34. Mariuzza RA, Phillips SE, Poljak RJ (1987) The structural basis of antigen-antibody recognition. Annu Rev Biophys Biophys Chem 16:139-159
35. Kitamura K, Takahashi T, Yamaguchi T, Noguchi A, Noguchi A, Takashina K, Tsurumi H, Inagake M, Toyokuni T, Kakomori S (1991) Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. Cancer Res 51:4310-4315
36. Pedley RB, Boden JA, Boden R, Begent RHJ, Turner A, Haines AMR, King DJ (1994) The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br J Cancer 70:1126-1130
37. Delgado C, Pedley RB, Herraez A, Boden R, Boden JA, Keep PA, Chester KA, Fisher D, Begent RHJ, Francis GE (1996) Enhanced tumour specificity of an anti-carcinoembryonic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification. Br J Cancer 73:175-182
38. Earhart RH, Koeller JM, Davis HL (1981) Phase I trial of PCNU administered by 5-day courses. Cancer Treat Rep 65:835-840
39. Eno-Amooquaye EA, Searle F, Boden JA, Sharma SK, Burke PJ (1996) Altered biodistribution of an antibody-enzyme conjugate modified with polyethylene glycol. Br J Cancer 73:1323-1327
40. Wilman DE, Palmer BD, Denny WA (1995) Application of 15N nuclear magnetic resonance spectroscopy to the determination of the stability of aryl nitrogen mustards. J Med Chem 38:2256-2258
41. Gera S, Musch E, Osterheld HK, Loos U (1989) Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma. Cancer Chemother Pharmacol 23:76-80
42. Sharma SK, Bagshawe KD, Melton RG, Sherwood RF (1992) Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys 21:109-120
43. Sharma SK (1996) Immune response in ADEPT. Adv Drug Delivery Rev 22:369-376
44. Dhingra K, Fritsche H, Murray JL, Lobuglio AF, Khazaeli MB, Kelley S, Tepper MA, Grasela D, Buzdar A, Valero V, Booser D, Whealin H, Collins TJ, Pursley JM, Hortobagyi G (1995) Phase 1 clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res 55:3060-3067